KRAS and lung carcinoma: Simultaneous genomic changes may impact biological behaviors, such as treatment response; thus, the investigation of co-occurring genomic alterations could help to stratify KRAS-mutant lung cancer patients into distinct subgroups with distinctive therapeutic responses [24].